Suven Pharmaceuticals Limited Cash Flow Conversion Efficiency
Suven Pharmaceuticals Limited cash flow conversion efficiency. Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) has a cash flow conversion efficiency ratio of 0.013x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs255.04 Million ≈ $2.76 Million USD) by net assets (Rs19.81 Billion ≈ $214.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Suven Pharmaceuticals Limited (2019–2025)
Cash flow conversion efficiency of Suven Pharmaceuticals Limited from 2019 to 2025. This chart illustrates how Suven Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Suven Pharmaceuticals Limited (SUVENPHAR) share price today for real-time trading data and today's change.
Suven Pharmaceuticals Limited Cash Flow Conversion Ratio Explained
Suven Pharmaceuticals Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Suven Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Suven Pharmaceuticals Limited ranked by their cash flow conversion efficiency. Also see how much is Suven Pharmaceuticals Limited worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Max Financial Services Limited
NSE:MFSL
|
0.263x |
|
KONINKLIJKE VOP.UNSP.ADR
F:VPK
|
N/A |
|
Wintime Energy Co Ltd
SHG:600157
|
0.032x |
|
Texas Capital Bancshares, Inc.
NASDAQ:TCBI
|
0.024x |
|
Novanta Inc
F:1GSN
|
0.011x |
|
Union Bank of Taiwan Pref
TW:2838A
|
0.018x |
|
IOI Properties Group Bhd
KLSE:5249
|
0.011x |
|
Hanwha
KO:000880
|
0.032x |
Annual Cash Flow Conversion Efficiency for Suven Pharmaceuticals Limited (2019–2025)
The table below shows the annual cash flow conversion efficiency of Suven Pharmaceuticals Limited from 2019 to 2025. Review how much free cash does Suven Pharmaceuticals Limited generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs18.41 Billion ≈ $199.06 Million |
Rs2.88 Billion ≈ $31.16 Million |
0.157x | -10.44% |
| 2024-03-31 | Rs20.51 Billion ≈ $221.77 Million |
Rs3.58 Billion ≈ $38.77 Million |
0.175x | -32.73% |
| 2023-03-31 | Rs17.35 Billion ≈ $187.65 Million |
Rs4.51 Billion ≈ $48.76 Million |
0.260x | +20.26% |
| 2022-03-31 | Rs15.27 Billion ≈ $165.16 Million |
Rs3.30 Billion ≈ $35.69 Million |
0.216x | -33.46% |
| 2021-03-31 | Rs11.81 Billion ≈ $127.70 Million |
Rs3.83 Billion ≈ $41.47 Million |
0.325x | -34.05% |
| 2020-03-31 | Rs8.45 Billion ≈ $91.36 Million |
Rs4.16 Billion ≈ $44.98 Million |
0.492x | +476.64% |
| 2019-03-31 | Rs5.90 Billion ≈ $63.84 Million |
Rs504.05 Million ≈ $5.45 Million |
0.085x | -- |
About Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more